Prophylaxis of Pneumocystis carinii pneumonia with atovaquone in children with leukemia

Cancer

Volumn 109, Issue 8, 2007, Pages 1654-1658

  Madden, Renee M ^a   Pui, Ching Hon ^a   Hughes, Walter T ^a   Flynn, Patricia M ^a   Leung, Wing ^a  

^a ST JUDE CHILDREN S RESEARCH HOSPITAL   (United States)

Author keywords

Atovaquone; Oncology; Opportunistic infection; Pediatric; Pneumocystis carinii

Indexed keywords

ATOVAQUONE; COTRIMOXAZOLE;

ACUTE GRANULOCYTIC LEUKEMIA; ACUTE LEUKEMIA; ACUTE LYMPHOBLASTIC LEUKEMIA; CANCER PATIENT; DRUG EFFICACY; DRUG TOLERABILITY; FEMALE; HUMAN; INCIDENCE; MAJOR CLINICAL STUDY; MALE; NONHUMAN; PNEUMOCYSTIS CARINII; PNEUMOCYSTIS PNEUMONIA; PRESCHOOL CHILD; PRIORITY JOURNAL; REMISSION; RETROSPECTIVE STUDY; REVIEW; SCHOOL CHILD; TREATMENT DURATION;

CHILD; FEMALE; HUMANS; IMMUNOCOMPROMISED HOST; LEUKEMIA; MALE; OPPORTUNISTIC INFECTIONS; PNEUMOCYSTIS CARINII; PNEUMONIA, PNEUMOCYSTIS; RETROSPECTIVE STUDIES;

EID: 34247127785     PISSN: 0008543X     EISSN: 10970142     Source Type: Journal    
DOI: 10.1002/cncr.22562     Document Type: Review

References (32)

1. Hughes WT, Anderson DC.Pneumocystis carinii pneumonia. In: Feigin RD, Cherry JD, Demmler GJ, Kaplan SL, eds. Textbook of Pediatric Infectious Diseases. 5th ed. Philadelphia: Saunders/Elsevier Science; 2004:2773-2782.
2. Dauzier G, Willis T, Barnett RN. Pneumocystis carinii pneumonia in an infant. Am J Pathol. 1956;26:787-793.
3. Patterson JH, Lindsey IL, Edwards ES, Logan WD. Pneumocystis carinii pneumonia and altered host resistance: treatment of one patient with pentamidine isethionate. Pediatrics. 1966;38:388-397.
4. Johnson HD, Johnson WW. Pneumocystis carinii pneumonia in children with cancer. JAMA. 1970;214:1067-1073.
5. Perera DR, Western KA, Johnson HD, Johnson WW, Schultz MG, Akers PV. Pneumocystis carinii pneumonia in a hospital for children. JAMA. 1970;214:1074-1078.
6. Hughes WT, Price RA, Kim HK, Coburn TP, Grigsby D, Feldman S. Pneumocystis carinii pneumonitis in children with malignancies. J Pediatr. 1973;82:404-415.
7. Hughes WT, Feldman S, Chaudhary SC, Ossi MJ, Cox F, Sanyal SK. Comparison of pentamidine isethionate and trimethoprim-sulfamethoxazole in the treatment of Pneumocystis carinii pneumonia. J Pediatr. 1978;92:258-291.
8. Hughes WT, Kuhn S, Chaudhary S, et al. Successful chemoprophylaxis for Pneumocystis carinii pneumonitis. N Engl J Med. 1977;297:1419-1426.
9. Hughes WT, Rivera GK, Schell MJ, Thornton D, Lott L. Successful intermittent chemoprophylaxis for Pneumocystis carinii pneumonitis. N Engl J Med. 1987;316:1627-1632.
10. Gordin FM, Simon GL, Wofsy CB, Mills J. Adverse reactions to trimethoprim-sulfamethoxazole in patients with the acquired immunodeficiency syndrome. Ann Int Med. 1984;100:495-499.
11. Chan C, Montaner J, Lefebvre EA, et al. Atovaquone suspension compared with aerosolized pentamidine for prevention of Pneumocystis carinii pneumonia in human immunodeficiency virus-infected subjects intolerant of trimethoprim or sulfonamides. J Infect Dis. 1999;180:369-376.
12. Hughes W, Dorenbaum A, Yogev R, et al. Phase I safety and pharmacokinetics study of micronized atovaquone in human immunodeficiency virus-infected infants and children. Antimicrob Agents Chemother. 1998;42:1315-1318.
13. Pui CH, Mahmoud HH, Rivera GK, et al. Early intensification of intrathecal chemotherapy virtually eliminates central nervous system relapse in children with acute lymphoblastic leukemia. Blood. 1998;92:411-415.
14. Pui CH, Sandlund JT, Pei D, et al. Improved outcome for children with acute lymphoblastic leukemia: results of Total Therapy Study XIIIB at St Jude Children's Research Hospital. Blood. 2004;104:2690-2696.
15. Kishi S, Griener J, Cheng C, et al. Homocysteine, pharmacogenetics, and neurotoxicity in children with leukemia. J Clin Oncol. 2003;21:3084-3091.
16. Pui CH, Relling MV, Sandlund JT, et al. Total Therapy Study XV for newly diagnosed childhood acute lymphoblastic leukemia: study design and preliminary results. Ann Hematol. 2006;85(Suppl 1):88-91.
17. Ribeiro RC, Razzouk BI, Pounds S, et al. Successive clinical trials for childhood acute myeloid leukemia at St. Jude Children's Research Hospital, from 1980-2000. Leukemia. 2005;19:2125-2129.
18. Rubnitz J, Razzouk B, Bowman P, et al. Improved remission induction rate of childhood AML: preliminary results of the AML02 trial. [Abstract]. Blood. 2005;106:275a.
19. Lyytikainen O, Elonen E, Lautenschlager I, et al. Pneumocystis carinii pneumonia in adults with acute leukemia; is there a need for primary chemoprophylaxis? Eur J Haematol. 1996;56:188-189.
20. Poulsen A, Demeny AK, Bang Plum C, et al. Pneumocytsis carinii pneumonia during maintenance treatment of childhood acute lymphoblastic leukemia. Med Pediatr Oncol. 2001;37:20-23.
21. Hughes WT, Leong G, Kramer F, et al. Comparison of atovaquone (566C80) with trimethoprim-sulfamethoxazole to treat Pneumocystis carinii pneumonia in patients with AIDS. N Engl J Med. 1993;328:1521-1527.
22. Cotton D. Atovaquone (Mepron) suspension approved by the FDA. AIDS Clin Care. 1995;7:62.
23. Hughes WT. Use of dapsone in the prevention and treatment of Pneumocystis carinii pneumonia: a review. Clin Infect Dis. 1998;27:191-204.
24. El-Sadr WM, Murphy RL Yurik TM, et al. Atovaquone compared with dapsone for the prevention of Pneumocystis carinii pneumonia in patients with HIV infection who cannot tolerate trimethoprim, sulfonamides or both. N Engl J Med. 1998;339:1889-1895.
25. Dohn MN, Weinberg WG, Torres RA, et al. Oral atovaquone compared with intravenous pentamidine for Pneumocystis carinii pneumonia in patients with AIDS. Ann Intern Med. 1994;121:174-180.
26. Mandrell BN, McCormick JN. Dapsone-induced methemoglobinemia in pediatric oncology patients: case examples. J Pediatr Oncol Nurs. 2001;18:224-228.
27. Williams S, MacDonald P, Hoyer JD, et al. Methemoglobinemia in children with acute lymphoblastic leukemia receiving dapsone for Pneumocystis carinii pneumonia prophylaxis: a correlation with cytochrome b5 reductase enzyme levels. Pediatr Blood Cancer. 2005;44:55-62.
28. Hughes WT, Dankner WM, Yogev R, et al. Comparison of atovaquone and azithromycin with trimethoprim-sulfamethoxazole for the prevention of serious bacterial infections in children with HIV infection. Clin Infect Dis. 2005;40:136-145.
29. Colby C, McAfee SL, Sackstein R, et al. A prospective randomized trial comparing the toxicity and safety of atovaquone with trimethoprim/ sulfamethoxazole as Pneumocystis carinii pneumonia prophylaxis following autologous peripheral blood stem cell transplantation. Bone Marrow Transplant. 1999;24:897-902.
30. Hughes WT. Prevention of infections in patients with T cell defects. Clin Infect Dis. 1993;17:S368-371.
31. Meyers B, Borrego F, Papanicolaou G. Pneumocystis carinii pneumonia prophylaxis with atovaquone in trimethoprim-sulfamethoxazole intolerant orthotopic liver transplant patients: a preliminary study. Liver Transplant. 2001;7:750-751.
32. Van de Poll MEC, Relling MV, Schuetz EG, et al. The effect of atovaquone on etoposide pharmacokinetics in children with acute lymphoblastic leukemia. Cancer Chemother Pharmacol. 2001;47:467-472.